These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25325525)

  • 1. Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm.
    Finks SW; Campbell JD
    Nurse Pract; 2014 Nov; 39(11):45-51. PubMed ID: 25325525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
    Alford JC; Saseen JJ; Allen RR; Nair KV
    Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.
    Tuchscherer RM; Nair K; Ghushchyan V; Saseen JJ
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):27-34. PubMed ID: 25348907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin interactions with other drugs.
    Florentin M; Elisaf MS
    Expert Opin Drug Saf; 2012 May; 11(3):439-44. PubMed ID: 22416996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians.
    Kerr KP; Mate KE; Magin PJ; Marley J; Stocks NP; Disler P; Pond CD
    J Clin Pharm Ther; 2014 Aug; 39(4):383-9. PubMed ID: 24702306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does simvastatin cause more myotoxicity compared with other statins?
    Backes JM; Howard PA; Ruisinger JF; Moriarty PM
    Ann Pharmacother; 2009 Dec; 43(12):2012-20. PubMed ID: 19920157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2004 Jun; 93(11):1417-8, A9. PubMed ID: 15165929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New simvastatin dosing recommendations.
    Med Lett Drugs Ther; 2011 Aug; 53(1370):61-2. PubMed ID: 21836544
    [No Abstract]   [Full Text] [Related]  

  • 9. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interactions between statins and macrolide antibiotics].
    Molden E; Andersson KS; Jacobsen D
    Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1660-1. PubMed ID: 17571108
    [No Abstract]   [Full Text] [Related]  

  • 11. Fixed-dose combination therapy with statins: strengths, limitations, and clinical and regulatory considerations.
    Hennekens CH
    Am J Cardiovasc Drugs; 2008; 8(3):155-60. PubMed ID: 18533736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.
    Page SR; Yee KC
    Intern Med J; 2014 Jul; 44(7):690-3. PubMed ID: 25041770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Team-based approach to addressing simvastatin safety concerns.
    Robinson M; Gunning K; Pippitt K; McAdam-Marx C; Jennings BT
    J Am Pharm Assoc (2003); 2013; 53(5):539-44. PubMed ID: 24030132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin safety and drug interactions: clinical implications.
    Bottorff MB
    Am J Cardiol; 2006 Apr; 97(8A):27C-31C. PubMed ID: 16581325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhabdomyolysis in association with simvastatin and amiodarone.
    Roten L; Schoenenberger RA; Krähenbühl S; Schlienger RG
    Ann Pharmacother; 2004 Jun; 38(6):978-81. PubMed ID: 15069169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin safety: lessons from new drug applications for marketed statins.
    Jacobson TA
    Am J Cardiol; 2006 Apr; 97(8A):44C-51C. PubMed ID: 16581328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
    Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of simvastatin-amiodarone drug interaction alert on appropriate prescribing.
    Prom R; Umscheid CA; Kasbekar N; Spinler SA
    Am J Health Syst Pharm; 2013 Nov; 70(21):1878-9. PubMed ID: 24128959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.